menu
    • menu
    [{"orgOrder":0,"company":"Berg Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Not Applicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Berg Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ubidecarenone","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Berg Health"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vitamin K1","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Vitamin K1

    Menu

    Vitamin K1

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            BioAsia
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin K1

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glenmark Pharma Edges Higher after US Launch of Coagulation Disorder Drug Phytonadione

                            Details : Phytonadione is indicated for coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.

                            Product Name : Vitamin K1-Generic

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : Vitamin K1

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GLAND PHARMA LIMITED

                            India arrow
                            BioAsia
                            Not Confirmed

                            GLAND PHARMA LIMITED

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin K1

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gland Pharma Receives USFDA Approval for Phytonadione Injectable Emulsion

                            Details : Phytonadione is indicated for coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2024

                            Lead Product(s) : Vitamin K1

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BPGbio

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            BPGbio

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Berg Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

                            Details : BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.

                            Product Name : BPM 31510

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2023

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Berg Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Berg Health

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Vitamin K1,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Pat...

                            Details : Abstract titled "Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM31510-IV treatment in advanced glioblastoma multiforme patients" will be presented at the ASCO meeting.

                            Product Name : BPM31510

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2021

                            Lead Product(s) : Ubidecarenone,Vitamin K1,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth